News

PMLive1h
Bayer’s Kerendia granted FDA approval for new heart failure indication
Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.
Medical Dialogues2h
FDA Expands Finerenone Indication to Include Heart Failure
The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...
FDA approves Kerendia for heart failure with ejection fraction of 40% or higher
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
Pharmabiz2h
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
Daily Jang20h
FDA approves Kerendia for cardiac failure with LVEF ≥40 percent
In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...